

Endokrinologische Prävention und Therapie der Osteoporose im Alter.

A. Römmler

ZS Orthomol Med 2006;1:22-26

Literatur

- 1 Ahlborg HG, Johnell O, Karlsson MK. Long term effects of oestrogen therapy on bone loss in postmenopausal women: a 23 year prospective study. *BJOG*. 2004 Apr;111(4):335-9
- 2 Arlt W, Callies F, Koehler I et al. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. *J Clin Endocrinol Metab* (2001),86,4686-92
- 3 Arlt W, Haas J, Callies F et al. Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. *J Clin Endocrinol Metab* (1999),84,2170-6
- 4 Arrenbrecht S, Boermans AJ. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial. *Osteoporos Int*. 2002;13(2):176-83
- 5 Bagger YZ, Tanko LB, Alexandersen P et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. *Bone*. 2004 Apr;34(4):728-35
- 6 Banks E, Beral V, Reeves G et al. Million Women Study Collaborators. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. *JAMA*. 2004 May 12;291(18):2212-20
- 7 Barrett-Connor E, Mueller JE, von Mühlen DG et al. Low levels of estradiol are associated with vertebral fractures in older men, but not women: The Rancho Bernardo Study. *J Clin Endocrinol Metab* (2000),85,219-23
- 8 Barrett-Connor E, Young R, Notelovitz M et al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. *J Reprod Med*. 1999 Dec;44(12):1012-20
- 9 Basaria S, Dobs AS: Hypogonadism and androgen replacement therapy in elderly men. *Am J Med* 2001;110:563-72
- 10 Baulieu EE, Thomas G, Legrain S et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge study to a sociobiomedical issue. *Proc Nat Acad Sci* 2000;97(8): 4279-84
- 11 Behre HM, von Eckardstein S, Kliesch S, Nieschlag E. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over seven to ten years. *Clin Endocrinol* 1999; 50:629-635.
- 12 Beld van den AW, de Jong FH, Grobbee DE et al. Measures of bioavailable serum testosterone and estradiol and their relationship with muscle strength, bone density, and body composition in elderly men. *J Clin Endocrinol Metab* (2000),85,3276-82
- 13 Bhattoa HP, Bettembuk P, Balogh A et al. The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. *Osteoporos Int*. 2004 May;15(5):396-404. Epub 2003 Dec 16
- 14 Bischoff HA, Stahelin HB, Dick W et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. *J Bone Miner Res*. 2003 Feb;18(2):343-51
- 15 Bolour S, Braunstein G. Testosterone therapy in women: a review. *Int J Impot Res*. 2005;17(5):399-408
- 16 Brixen KT, Christensen PM, Ejersted C, Langdahl BL. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. *Basic Clin Pharmacol Toxicol*. 2004 Jun;94(6):260-70
- 17 Bruner-Tran KL, Zhang Z, Eisenberg E et al. Down-regulation of Endometrial MMP-3 and MMP-7 Expression in vitro and Therapeutic Regression of Experimental Endometriosis in vivo by a Novel Nonsteroidal Progesterone Receptor Agonist, Tanaproget. *J Clin Endocrinol Metab*. 2006 Jan 17
- 18 Cameron DR, Braunstein GD. Androgen replacement therapy in women. *Fertil Steril*. 2004 Aug;82(2):273-89

- 19 Carlsten H. Immune responses and bone loss: the estrogen connection. *Immunol Rev.* 2005 Dec;208:194-206
- 20 Cauley JA, Robbins J, Chen Z et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. *JAMA.* 2003 Oct 1;290(13):1729-38
- 21 Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. *Immunol Rev.* 2005 Dec;208:207-27
- 22 Col NF, Bowlby LA, McGarry K. The role of menopausal hormone therapy in preventing osteoporotic fractures: a critical review of the clinical evidence. *Minerva Med.* 2005 Oct;96(5):331-42
- 23 Cooper C, Stakkestad JA, Radowicki S et al. Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. *Osteoporos Int.* 1999;9(4):358-66
- 24 Cosman F. The prevention and treatment of osteoporosis: a review. *MedGenMed.* 2005 May 11;7(2):73
- 25 Cranney A, Guyatt G, Griffith L et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. *Endocr Rev.* 2002 Aug;23(4):570-8
- 26 Cutter CB. Compounded percutaneous testosterone gel: use and effects in hypogonadal men *J Am Board Fam Pract.* 2001 Jan-Feb;14(1):22-32
- 27 Darby E, Anawalt BD. Male hypogonadism: an update on diagnosis and treatment.
- 28 Davis SR, Walker KZ, Strauss BJ. Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. *Menopause.* 2000 Nov-Dec;7(6):395-401
- 29 Davison SL, Davis SR. Androgens in women. *J Steroid Biochem Mol Biol.* 2003 Jun;85(2-5):363-6
- 30 de Lignieres B, de Vathaire F, Fournier S et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. *Climacteric.* 2002 Dec;5(4):332-40
- 31 Dennison EM, Arden NK, Kellingray S et al. Hormone replacement therapy, other reproductive variables and symptomatic hip osteoarthritis in elderly white women: a case-control study. *Br J Rheumatol.* 1998 Nov;37(11):1198-202
- 32 Dobs AS, Nguyen T, Pace C et al. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. *J Clin Endocrinol Metab.* 2002 Apr;87(4):1509-16
- 33 Ebert T, Jockenhovel F, Morales A, Shabsigh R. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel. *Eur Urol.* 2005 Feb;47(2):137-46
- 34 Erb A, Brenner H, Gunther KP et al. Hormone replacement therapy and patterns of osteoarthritis: baseline data from the Ulm Osteoarthritis Study. *Ann Rheum Dis.* 2000 Feb;59(2):105-9
- 35 Eriksen EF, Robins DA. Teriparatide: A bone formation treatment for osteoporosis. *Drugs Today (Barc).* 2004 Nov;40(11):935-48
- 36 Feldman HA, Longcope C, Derby CA et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. *J Clin Endocrinol Metab* (2002),87,589-98
- 37 Finkelstein JS, Hayes A, Hunzelman JL et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. *N Engl J Med.* 2003 Sep 25;349(13):1216-26. Epub 2003 Sep 20
- 38 Floter A, Nathorst-Boos J, Carlstrom K et al. Effects of combined estrogen/testosterone therapy on bone and body composition in oophorectomized women. *Gynecol Endocrinol.* 2005 Mar;20(3):155-60
- 39 Fournier A, Berrino F, Riboli E et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. *Int J Cancer.* 2005 Apr 10;114(3):448-54
- 40 Gambacciani M, Vacca F. Postmenopausal osteoporosis and hormone replacement therapy. *Minerva Med.* 2004 Dec;95(6):507-20

- 41 Genazzani AR, Inglese S, Lombardi I et al. Long-term low-dose dehydroepiandrosterone replacement therapy in aging males with partial androgen deficiency. *Aging Male* 2004;7: 133-43
- 42 Going S, Lohman T, Houtkooper L et al. Effects of exercise on bone mineral density in calcium-replete postmenopausal women with and without hormone replacement therapy. *Osteoporos Int.* 2003 Aug;14(8):637-43. Epub 2003 Jul 3
- 43 Gordon CM, Grace E, Emans SJ et al. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. *J Clin Endocrinol Metab.* 2002 Nov;87(11):4935-41
- 44 Grey AB, Cundy TF, Reid IR. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density of the hip and spine in postmenopausal osteoporosis. *Clin Endocrinol* 40 (1994) 671-7
- 45 Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. *J Am Geriatr Soc.* 2003 Jan;51(1):101-15
- 46 Grumbach MM, Auchus RJ. Estrogen: Consequences and implications of human mutations in synthesis and action. *J Clin Endocrinol Metab* (1999),84,4677-94
- 47 Hadji P, Kalder M, Gottschalk M et al. Knochengesundheit im Alter. *Gynäkologie* 2002; 35:975-86
- 48 Huber JC. Is the face of gynecology changing?? - A perspective. *Zentralbl Gynakol.* 1996;118(7):387-91
- 49 Isoniemi H, Appelberg J, Nilsson CG et al. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study. *J Hepatol.* 2001 Feb;34(2):299-305
- 50 Jo H, Ahn HJ, Kim EM et al. Effects of dehydroepiandrosterone on articular cartilage during the development of osteoarthritis. *Arthritis Rheumatism* 2004;50(8):2531-8
- 51 Jo H, Park JS, Kim EM et al. The in vitro effects of dehydroepiandrosterone on human osteoarthritic chondrocytes. *Osteoarthritis Cartilage.* 2003 Aug;11(8):585-94
- 52 Katznelson L et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. *J Clin Endocrinol Metab.* 1996;81(12):4358-65
- 53 Kaufman JM, Orwoll E, Goemaere S et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. *Osteoporos Int.* 2005 May;16(5):510-6. Epub 2004 Aug 18
- 54 Kenny AM, Prestwood KM, Gruman CA et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. *J Gerontol A Biol Sci Med Sci* 2001;56(5): M266-72
- 55 Khosla S et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. *J Clin Endocrinol Metab* (2001),86,3555-61
- 56 King JA, Wisniewski AB, Bankowski BJ et al. Long term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. *J Clin Endocrinol Metab.* 2005 Nov 8
- 57 Labrie F, Diamond P, Cusan L et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. *J Clin Endocrinol Metab* 1997;82(10): 3498-505
- 58 Lambrinoudaki I, Christodoulakos G, Aravantinos L et al. Endogenous sex steroids and bone mineral density in healthy Greek postmenopausal women. *J Bone Miner Metab.* 2006;24(1):65-71
- 59 Landin-Wilhelmsen K, Wilhelmsen L, Bengtsson BA. Postmenopausal osteoporosis is more related to hormonal aberrations than to lifestyle factors. *Clin Endocrinol (Oxf).* 1999 Oct;51(4):387-94
- 60 Landin-Wilhelmsen K, Nilsson A, Bosaeus I, Bengtsson BA. Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial. *J Bone Miner Res.* 2003 Mar;18(3):393-405
- 61 Lane NE, Kelman A. A review of anabolic therapies for osteoporosis. *Arthritis Res Ther.* 2003;5(5):214-22. Epub 2003 Aug 5

- 62 Lane NE, Nevitt MC, Hochberg MC et al. Progression of radiographic hip osteoarthritis over eight years in a community sample of elderly white women. *Arthritis Rheum.* 2004 May;50(5):1477-86
- 63 Leder BZ, LeBlanc KM, Schoenfeld DA et al. Differential effects of androgens and estrogens on bone turnover in normal men. *J Clin Endocrinol Metab.* (2003),88(1),204-10
- 64 Leifke E, Gorenou V, Wichers C et al. Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men; cross-sectional data from a healthy male cohort. *Clin Endocrinol* (2000),53,689-95
- 65 Liu PY, Swerdloff RS, Veldhuis JD. Clinical review 171: The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. *J Clin Endocrinol Metab.* 2004 Oct;89(10):4789-96
- 66 Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. *J Bone Miner Res.* 2003 Jan;18(1):18-23
- 67 Marcus R, Wong M, Heath H 3rd, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. *Endocr Rev.* 2002 Feb;23(1):16-37
- 68 Mease PJ, Ginzler EM, Gluck OS et al. Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy. *J Rheumatol.* 2005 Apr;32(4): 616-21
- 69 Meinhardt U, Mullis PE. The aromatase cytochrome P-450 and its clinical impact. *Horm Res* (2002),57,145-52
- 70 Michael H, Harkonen PL, Vaananen HK, Hentunen TA. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. *J Bone Miner Res.* 2005 Dec;20(12):2224-32. Epub 2005 Aug 1
- 71 Minetto M et al. Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome. *Osteoporos Int.* 2004;15(11):855-61
- 72 Morales AJ, Nolan JJ, Nelson JC et al. Effects of Replacement Dose of Dehydroepiandrosterone in Men and Women of Advancing Age. *J Clin Endocrinol Metab* 1994;78(6): 1360-7
- 73 Mosekilde L, Beck-Nielsen H, Sorensen OH et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. *Maturitas.* 2000 Oct 31;36(3):181-93
- 74 Mudali S, Dobs AS. Effects of testosterone on body composition of the aging male. *Mech Ageing Dev.* 2004;125(4):297-304
- 75 Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med.* 2001 May 10;344(19): 1434-41
- 76 Nelson HD, Humphrey LL, Nygren P et al. Postmenopausal hormone replacement therapy: Scientific review. *JAMA.* 2002 Aug 21;288(7):872-81
- 77 Nevitt MC, Cummings SR, Lane NE, Hochberg MC, Scott JC, Pressman AR, Genant HK, Cauley JA. Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Study of Osteoporotic Fractures Research Group. *Arch Intern Med.* 1996 Oct 14;156(18):2073-80
- 78 Notelovitz M. Androgen effects on bone and muscle. *Fertil Steril* 2002 Apr;77 Suppl 4:34-41
- 79 Ohmori N et al. Osteoporosis is more prevalent in adrenal than in pituitary Cushing's syndrome. *Endocr J.* 2003;50:1-7
- 80 Olney RC. Regulation of bone mass by growth hormone. *Med Pediatr Oncol* 2003 Sep;41(3):228-34
- 81 Pfeifer M, Minne HW. Prävention von Stürzen und Frakturen bei älteren Menschen. *Dtsch Arztebl* 2006;103:A116-7
- 82 Prelevic GM, Bartram C, Wood J et al. Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women. *Gynecol Endocrinol.* 1996 Dec;10(6):413-20
- 83 Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. *JAMA.* 2003 Aug 27;290(8):1042-8

- 84 Ravn P, Warming L, Christgau S, Christiansen C. The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy. *Bone*. 2004 Nov;35(5):1216-21
- 85 Römmler A. Östrogene für Mann und Frau. Niedrige Basalspiegel sind die Richtschnur. In: Römmler A, Wolf AS. (Hrsg.) *Anti-Aging Sprechstunde, Teil 1: Leitfaden für Einsteiger*. Congress Compact Verlag, Berlin, (2002),61-94
- 86 Römmler A. Androgene für Mann und Frau. DHEA – Androstendion - Testosteron. In: Römmler A, Wolf AS. (Hrsg.) *Anti-Aging Sprechstunde, Teil 1: Leitfaden für Einsteiger*. Congress Compact Verlag, Berlin, 2002; 103-38
- 87 Römmler A. Paradigmenwechsel bei der Substitution mit Östrogenen. *OM Zeitschrift für Orthomolekulare Medizin*. 2003;3:13-17
- 88 Römmler A. Adrenopause und Dehydroepiandrosteron: Pharmakotherapie versus Substitution. *Gynakol Geburtshilfliche Rundsch* 2003;43:79-90
- 89 Römmler A. Andropause: Differenzierte Diagnostik und Substitution mit DHEA, Testosteron und Estrogenen. In: Wolf A, Römmler A, Moltz L, Klentze M (Hrsg). *Anti Aging Medizin 2003*, congress compact verlag Berlin, 2004,195-219
- 90 Römmler A. Neubewertung der HRT: Orale versus transdermale Östrogene sowie Progestagene versus Progesteron - Wege zur Risikoreduktion. In: Wolf A, Römmler A, Moltz L, Klentze M (Hrsg). *Anti Aging Medizin 2003*, congress compact verlag Berlin, 2004, 168-94
- 91 Römmler A: Estrogene für den Mann? *ÄP Urol Nephrol* 2004;3, 30-32
- 92 Römmler A: Substitution mit DHEA – klinische Studien bei Mann und Frau. *ZS Orthomol Med* 2004; 3, 22-5
- 93 Römmler A. Risikoreduktion einer Hormonersatzbehandlung (ERT/HRT). Transdermale Östrogene und mikronisiertes Progesteron oral. *Anti Aging for Professionals* 2005;1:44-50. (www.anti-aging-professionals.com)
- 94 Rosen T, Wilhelmsen L, Landin-Wilhelmsen K et al. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. *Eur J Endocrinol*. 1997 Sep;137(3):240-5
- 95 Roy TA, Blackman MR, Harman SM et al. Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. *Am J Physiol Endocrinol Metab* (2002),283,E284–E294
- 96 Saad F, Hoesl CE, Oettel M, Fauteck JD, Römmler A. Dehydroepiandrosterone treatment in the aging male - what should the urologist know? *Eur Urol*. 2005 Nov;48(5):724-33
- 97 Sanchez C, Deberg MA, Piccardi N et al. Osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by interleukin-6, -1beta and oncostatin M pre-treated non-sclerotic osteoblasts. *Osteoarthritis Cartilage*. 2005 Nov;13(11):979-87
- 98 Sarrel PM. Androgen deficiency: menopause and estrogen-related factors. *Fertil Steril*. 2002 Apr;77 Suppl 4:S63-7
- 99 Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. *Lancet*. 2003 Aug 9;362(9382):428-32
- 100 Sharp CA, Evans SF, Risteli L et al. Effects of low- and conventional-dose transcutaneous HRT over 2 years on bone metabolism in younger and older postmenopausal women. *Eur J Clin Invest* 1996 Sep;26(9):763-71
- 101 Sharpe RM: The role of oestrogen in the male. *Trends Endocrinol Metab* 1998;9:371-7
- 102 Shin MH, Rhie GE, Park CH et al. Modulation of collagen metabolism by the topical application of dehydroepiandrosterone to human skin. *J Invest Dermatol*. 2005 Feb;124(2):315-23
- 103 Smith NL, Heckbert SR, Lemaitre RN et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. *JAMA*. 2004 Oct 6;292(13):1581-7
- 104 Snyder PJ et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. *J Clin Endocrinol Metab*. 1999; 84:1966 –72
- 105 Sorensen MB, Rosenfalck AM, Hojgaard L, Ottesen B. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. *Obes Res*. 2001 Oct;9(10):622-6
- 106 Sowers MR, Jannausch M, McConnell D et al. Hormone predictors of bone mineral density changes during the menopausal transition. *J Clin Endocrinol Metab*. 2006 Jan 10

- 107 Steidle C, Schwartz S, Jacoby K et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. *J Clin Endocrinol Metab.* 2003 Jun;88(6):2673-81
- 108 Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. *Bone* 2003 Dec;33(6):919-26
- 109 Stevenson M, Lloyd Jones M, De Nigris E et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. *Health Technol Assess.* 2005 Jun;9(22):1-160
- 110 Straub RH, Konecna L, Hrach S et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. *J Clin Endocrinol Metab.* 1998 Jun;83(6):2012-7
- 111 Sudhir K, Komesaroff PA: Cardiovascular actions of estrogens in men. *J Clin Endocrinol Metab* (1999),84,3411-25
- 112 Sun Y, Mao M, Sun L et al. Treatment of osteoporosis in men using dehydroepiandrosterone sulfate. *Chin Med J* 2002;115(3): 402-4
- 113 Svensson J, Bengtsson BA, Rosen T et al. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. *J Clin Endocrinol Metab.* 2004 Jul;89(7):3306-12
- 114 Svensson J, Johannsson G. Long-term efficacy and safety of somatropin for adult growth hormone deficiency. *Treat Endocrinol.* 2003;2(2):109-20
- 115 Swerdloff RS, Wang C. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. *Aging Male.* 2003 Sep;6(3):207-11
- 116 Takayanagi R, Goto K, Suzuki S et al. Dehydroepiandrosterone (DHEA) as a possible source for estrogen formation in bone cells: correlation between bone mineral density and serum DHEA-sulfate concentration in postmenopausal women, and the presence of aromatase to be enhanced by 1,25-dihydroxyvitamin D3 in human osteoblasts. *Mechanisms of Ageing and Development* 2002; 123: 1107-14
- 117 Thijssen JH Overview on the effects of progestins on bone. *Maturitas* 2003 Dec;46 Suppl 1:S77-87
- 118 Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. *BMC Musculoskelet Disord.* 2001;2:7. Epub 2001 Nov 6
- 119 Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. *JAMA.* 2001 Jun 13;285(22):2891-7
- 120 *Treat Endocrinol.* 2005;4(5):293-309
- 121 Vanderschueren D, Venken K, Ophoff J et al. Sex Steroids and the Periosteum: Reconsidering the Role of Androgens and Estrogens in Periosteal Expansion. *J Clin Endocrinol Metab.* 2005 Nov 22
- 122 Vestergaard P, Mosekilde L. Fracture risk is decreased in acromegaly--a potential beneficial effect of growth hormone. *Osteoporos Int.* 2004 Feb;15(2):155-9. Epub 2003 Nov 19
- 123 Villareal DT, Holloszy JO, Kohrt WM: Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. *Clin Endocrinol* 2000;53: 561-68
- 124 Von Muhlen D, Morton D, Von Muhlen CA, Barrett-Connor E. Postmenopausal estrogen and increased risk of clinical osteoarthritis at the hip, hand, and knee in older women. *J Womens Health Gend Based Med.* 2002 Jul-Aug;11(6):511-8
- 125 Wang C, Cunningham G, Dobs A et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. *J Clin Endocrinol Metab.* 2004 May;89(5):2085-98
- 126 Warming L, Ravn P, Christiansen C. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis. *Maturitas.* 2005 Feb 14;50(2):78-85
- 127 Wasnich RD, Bagger YZ, Hosking DJ et al. Early Postmenopausal Intervention Cohort Study Group. Changes in bone density and turnover after alendronate or estrogen withdrawal. *Menopause.* 2004 Nov-Dec;11(6 Pt 1):622-30

- 128 Wells G, Tugwell P, Shea B et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. *Endocr Rev.* 2002 Aug;23(4):529-39
- 129 Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. *Am J Med.* 1998 Mar;104(3):219-26
- 130 Wolf AS. Progestagene sind nicht Progesteron. In: Römmler A, Wolf AS. (Hrsg.) *Anti-Aging Sprechstunde, Teil 1: Leitfaden für Einsteiger.* Congress Compact Verlag, Berlin, 2002; 95-102
- 131 Wuster C, Abs R, Bengtsson BA et al. KIMS Study Group and the KIMS International Board. Pharmacia & Upjohn International Metabolic Database. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. *J Bone Miner Res.* 2001 Feb;16(2):398-405
- 132 Wüster C. Wachstumshormon bei Erwachsenen. *Anti Aging for Professionals.* 2005;2:42-50 (www.anti-aging-professionals.com)
- 133 Zhang Y, McAlindon TE, Hannan MT et al. Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: the Framingham Study. *Arthritis Rheum.* 1998 Oct;41(10):1867-73
- 134 Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. *J Clin Endocrinol Metab.* 1995 Apr;80(4):1429-30